Amendment 34: DRIVe EZ Broad Agency Announcement

EZBAA-22-100-SOL-00003

Amendment #034

Office of Biomedical Advanced Research and Development Authority Division of Research, Innovation & Ventures (DRIVe)
Easy Broad Agency Announcement EZBAA-22-100-SOL-00003

The purpose of Amendment #034 is the following:

1) Reopen the following Area of Interest (AOI):
AOI #22: ReBooT
2) Revise the following Area of Interest (AOI):
AOI #22: ReBooT
3) Pause the following Area of Interest (AOI):

AOI#24: RePAIR

EZBAA-22-100-SOL-00003

Amendment #034

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Reopening the following research Area of Interest (AOI): AOI #22: ReBooT

2)

Revising the following research Area of Interest (AOI): AOI #22: ReBooT
We are now seeking abstract submissions for the following AOI:

AOI #22: ReBooT

Antiviral therapeutics have the potential to impact multiple viruses that utilize conserved mechanisms of action for infection, require specific host proteins for infection, or share conserved viral proteins. Typically, antivirals are advanced for one indication, but they may have efficacy against other related pathogens. As the commercial market for products targeting filoviruses is small and evaluation of candidates requires access to BSL4 facilities, product developers have limited incentive to test candidate products against filoviruses. Under the ReBooT program, the Antivirals and Antitoxins (AVAT) program aims to support the testing and evaluation of candidate antiviral therapeutics that have been developed past Phase 1 clinical trials for another indication, but which have a mechanism of action likely to be effective against filoviruses (including but not limited to Ebola virus, Sudan virus, and Marburg virus). Successful efforts could be considered for follow-on support under an EZ-BAA+ award or under the BARDA Broad Area Announcement (BAA-22-100-SOL-00003).
BARDA is requesting abstract submissions for projects that evaluate investigative or licensed/approved therapeutics as medical countermeasure (MCM) against filoviruses. The candidates may include direct acting antivirals or host directed products. Candidates should either have the potential to complement existing therapies by improving patient outcomes or serve as effective monotherapies against filoviruses. Broad spectrum antivirals with anticipated efficacy against multiple species or genera of viruses are preferred. Also, products that are orally available and have room temperature storage will be